Abstract

Programmed necrosis has been proven vital for organism development and homeostasis maintenance. Its regulatory effects on functional activity of the immune system, as well as on pathways regulating the death mechanisms in cells with diminished apoptotic activity, including malignant cells, have been confirmed. There is also increasing evidence indicating necrosis involvement in many human pathologies. Contrary to previous beliefs, necrosis is not only a passive, pathological, gene-independent process. However, the current knowledge regarding molecular regulation of programmed necrosis is scarce. In part this is due to the multiplicity and complexity of signaling pathways involved in programmed necrosis, as well as the absence of specific cellular markers identifying this process, but also the ambiguous and imprecise international terminology. This review presents the current state of the art on molecular mechanisms of programmed necrosis. In particular, its specific and frequent form, necroptosis, is discussed. The role of RIP1 and RIP3 kinases in this process is presented, as well as the diverse pathways induced by ligation of tumor necrosis factor α, to its receptor, TNFR1, i.e. cell survival, apoptosis or necroptosis.

References

• 1. Alameda J.P., Moreno-Maldonado R., Navarro M., Bravo A., RamírezA., Page A., Jorcano J.L., Fernández-Aceñero M.J., CasanovaM.L.: An inactivating CYLD mutation promotes skin tumor progressionby conferring enhanced proliferative, survival and angiogenicproperties to epidermal cancer cells. Oncogene, 2010; 29: 6522-6532
  Google Scholar
• 2. Burz C., Berindan-Neagoe I., Balacescu O., Irimie A.: Apoptosis incancer: key molecular signaling pathways and therapy targets. ActaOncol., 2009; 48: 811-821
  Google Scholar
• 3. Ch’en I.L., Tsau J.S., Molkentin J.D. Komatsu M., Hedrick S.M.:Mechanisms of necroptosis in T cells. J. Exp. Med., 2011; 208: 633-641
  Google Scholar
• 4. Chaabane W., User S.D., El-Gazzah M. Jaksik R., Sajjadi E., Rzeszowska-WolnyJ., Los M.J.: Autophagy, apoptosis, mitoptosis andnecrosis: interdependence between those pathways and effects oncancer. Arch. Immunol. Ther. Exp., 2013; 61: 43-58
  Google Scholar
• 5. Chipuk J.E., Bouchier-Hayes L., Green D.R.: Mitochondrial outermembrane permeabilization during apoptosis: the innocent bystanderscenario. Cell Death Differ., 2006; 13: 1396-1402
  Google Scholar
• 6. Cho Y.S., Challa S., Moquin D. Genga R., Ray T.D., Guildford M.,Chan F.K.: Phosphorylation-driven assembly of the RIP1-RIP3 complexregulates programmed necrosis and virus-induced inflammation.Cell, 2009; 137: 1112-1123
  Google Scholar
• 7. Christofferson D.E., Yuan J.: Necroptosis as an alternative formof programmed cell death. Curr. Opin. Cell Biol., 2010; 22: 263-268
  Google Scholar
• 8. Degterev A., Huang Z., Boyce M. Li Y., Jagtap P., Mizushima N.,Cuny G.D., Mitchison T.J., Moskowitz M.A., Yuan J.: Chemical inhibitorof nonapoptotic cell death with therapeutic potential for ischemicbrain injury. Nat. Chem. Biol., 2005; 1: 112-119
  Google Scholar
• 9. Degterev A., Yuan J.: Expansion and evolution of cell death programmes. Nat. Rev. Mol. Cell Biol., 2008; 9: 378-390
  Google Scholar
• 10. Duprez L., Takahashi N., Van Hauwermeiren F. VandendriesscheB., Goossens V., Vanden Berghe T., Declercq W., Libert C., Cauwels A.,Vandenabeele P.: RIP kinase-dependent necrosis drives lethal systemicinflammatory response syndrome. Immunity, 2011; 35: 908-918
  Google Scholar
• 11. Elmore S.: Apoptosis: a review of programmed cell death. Toxicol.Pathol., 2007; 35: 495-516
  Google Scholar
• 12. Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P.: RIP1,a kinase on the crossroads of a cell’s decision to live or die. Cell DeathDiffer., 2007; 14: 400-410
  Google Scholar
• 13. Formigli L., Papucci L., Tani A. Schiavone N., Tempestini A., OrlandiniG.E., Capaccioli S., Orlandini S.Z.: Aponecrosis: morphologicaland biochemical exploration of a syncretic process of cell deathsharing apoptosis and necrosis. J. Cell. Physiol., 2000; 182: 41-49
  Google Scholar
• 14. Fulda S.: Caspase-8 in cancer biology and therapy. Cancer Lett.,2009; 281: 128-133
  Google Scholar
• 15. Fulda S.: The mechanism of necroptosis in normal and cancercells. Cancer Biol. Ther., 2013; 14: 999-1004
  Google Scholar
• 16. Fulda S., Debatin K.M.: Extrinsic versus intrinsic apoptosis pathwaysin anticancer chemotherapy. Oncogene, 2006; 25: 4798-4811
  Google Scholar
• 17. Galluzzi L., Kepp O., Krautwald S. Kroemer G., Linkermann A.:Molecular mechanisms of regulated necrosis. Semin. Cell Dev. Biol.,2014; 35: 24-32
  Google Scholar
• 18. Galluzzi L., Kroemer G.: Necroptosis: a specialized pathway ofprogrammed necrosis. Cell, 2008; 135: 1161-1163
  Google Scholar
• 19. Galluzzi L., Maiuri M.C., Vitale I. Zischka H., Castedo M., ZitvogelL., Kroemer G.: Cell death modalities: classification and pathophysiologicalimplications. Cell Death Differ., 2007; 14: 1237-1243
  Google Scholar
• 20. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H.,Blagosklonny M.V., Dawson T.M., Dawson V.L., El-Deiry W.S., FuldaS., Gottlieb E., Green D.R., Hengartner M.O., Kepp O., Knight R.A.,Kumar S. i wsp.: Molecular definitions of cell death subroutines:recommendations of the Nomenclature Committee on Cell Death 2012 Cell Death Differ., 2012; 19: 107-120
  Google Scholar
• 21. Glick D., Barth S., Macleod K.F.: Autophagy: cellular and molecularmechanisms. J. Pathol., 2010; 221: 3-12
  Google Scholar
• 22. Golstein P., Kroemer G.: Cell death by necrosis: towards a moleculardefinition. Trends Biochem. Sci., 2007; 32: 37-43
  Google Scholar
• 23. Guicciardi M.E., Gores G.J.: Life and death by death receptors.FASEB J., 2009; 23: 1625-1637
  Google Scholar
• 24. Han W., Li L., Qiu S. Lu Q., Pan Q., Gu Y., Luo J., Hu X.: Shikonincircumvents cancer drug resistance by induction of a necroptoticdeath. Mol. Cancer Ther., 2007; 6: 1641-1649
  Google Scholar
• 25. Hassan M., Watari H., AbuAlmaaty A., Ohba Y., Sakuragi N.: Apoptosisand molecular targeting therapy in cancer. Biomed. Res. Int.,2014; 2014: 150845
  Google Scholar
• 26. He S., Wang L., Miao L. Wang T., Du F., Zhao L., Wang X.: Receptorinteracting protein kinase-3 determines cellular necrotic responseto TNF-α. Cell, 2009; 137: 1100-1111
  Google Scholar
• 27. Helewski K.J., Kowalczyk-Ziomek G.I., Konecki J.: Apoptoza i martwica– dwie drogi do jednego celu. Wiad. Lek., 2006; 59: 679-684
  Google Scholar
• 28. Hitomi J., Christofferson D.E., Ng A. Yao J., Degterev A., XavierR.J., Yuan J.: Identification of a molecular signaling networkthat regulates a cellular necrotic cell death pathway. Cell, 2008;135: 1311-1323
  Google Scholar
• 29. Hu W., Kavanagh J.J.: Anticancer therapy targeting the apoptoticpathway. Lancet Oncol., 2003; 4: 721-729
  Google Scholar
• 30. Häcker G.: The morphology of apoptosis. Cell Tissue Res., 2000;301: 5-17
  Google Scholar
• 31. Jin Z., El-Deiry W.S.: Overview of cell death signaling pathways.Cancer Biol. Ther., 2005; 4: 139-163
  Google Scholar
• 32. Kelly K.J., Plotkin Z., Dagher P.C.: Guanosine supplementationreduces apoptosis and protects renal function in the setting of ischemicinjury. J. Clin. Invest., 2001; 108: 1291-1298
  Google Scholar
• 33. Khan K.H., Blanco-Codesido M., Molife L.R.: Cancer therapeutics:targeting the apoptotic pathway. Crit. Rev. Oncol. Hematol.,2014; 90: 200-219
  Google Scholar
• 34. Kopiński P.: Apoptoza limfocytów pęcherzykowych w wybranychśródmiąższowych chorobach płuc. Rozprawa habilitacyjna.Wydawnictwo Naukowe UMK, Bydgoszcz 2012
  Google Scholar
• 35. Kopiński P., Chorostowska-Wynimko J., Dyczek A., Giżycka A.:Apoptoza limfocytów pęcherzykowych. Część 1 – szlaki apoptozylimfocytów Pneumonol. Alergol. Pol., 2014; 82: 170-182
  Google Scholar
• 36. Kopinski P., Gizycka A., Chorostowska-Wynimko J.: Zaprogramowanaśmierć komórkowa: czy tylko apoptoza? Pol. Merk. Lekarski,2014; 37: 201-205
  Google Scholar
• 37. Krysko D.V., Vanden Berghe T., D’Herde K. Vandenabeele P.:Apoptosis and necrosis: detection, discrimination and phagocytosis.Methods, 2008; 44: 205-221
  Google Scholar
• 38. Lee E.W., Seo J., Jeong M., Lee S., Song J.: The roles of FADD inextrinsic apoptosis and necroptosis. BMB Rep., 2012; 45: 496-508
  Google Scholar
• 39. Lenardo M.J., Angleman S.B., Bounkeua V. Dimas J., Duvall M.G.,Graubard M.B., Hornung F., Selkirk M.C., Speirs C.K., Trageser C.,Orenstein J.O., Bolton D.L.: Cytopathic killing of peripheral bloodCD4(+) T lymphocytes by human immunodeficiency virus type 1appears necrotic rather than apoptotic and does not require env. J.Virol., 2002; 76: 5082-5093
  Google Scholar
• 40. Li H., Kobayashi M., Blonska M. You Y., Lin X.: Ubiquitination ofRIP is required for tumor necrosis factor α-induced NF-κB activation.J. Biol. Chem., 2006; 281: 13636-13643
  Google Scholar
• 41. Lin Y., Choksi S., Shen H.M., Yang Q.F., Hur G.M., Kim Y.S., TranJ.H., Nedospasov S.A., Liu Z.G.: Tumor necrosis factor-induced nonapoptoticcell death requires receptor-interacting protein-mediatedcellular reactive oxygen species accumulation. J. Biol. Chem., 2004;279: 10822-10828
  Google Scholar
• 42. Linkermann A., Bräsen J.H., Darding M. Jin M.K., Sanz A.B., HellerJ.O., De Zen F., Weinlich R., Ortiz A., Walczak H., Weinberg J.M., GreenD.R., Kunzendorf U., Krautwald S.: Two independent pathways ofregulated necrosis mediate ischemia-reperfusion injury. Proc. Natl.Acad. Sci. USA, 2013; 110: 12024-12029
  Google Scholar
• 43. Liu P., Xu B., Shen W., Zhu H., Wu W., Fu Y., Chen H., Dong H., ZhuY., Miao K., Xu W., Li J.: Dysregulation of TNFα-induced necroptoticsignaling in chronic lymphocytic leukemia: suppression of CYLDgene by LEF1. Leukemia, 2012; 26: 1293-1300
  Google Scholar
• 44. Malinowska I.: Rola apoptozy w patogenezie i leczeniu nowotworówukładu hematopoetycznego. Postępy Hig. Med. Dośw., 2004;58: 548-559
  Google Scholar
• 45. Marek Ł.: Rola apoptosomu w aktywacji prokaspazy 9. PostępyHig. Med. Dośw. 2013; 67: 54-64
  Google Scholar
• 46. Moriwaki K., Chan F.K.: Necrosis-dependent and independentsignaling of the RIP kinases in inflammation. Cytokine Growth FactorRev., 2014; 25: 167-174
  Google Scholar
• 47. Moujalled D.M., Cook W.D., Okamoto T. Murphy J., Lawlor K.E.,Vince J.E., Vaux D.L.: TNF can activate RIPK3 and cause programmednecrosis in the absence of RIPK1. Cell Death Dis., 2013; 4: e465
  Google Scholar
• 48. Murdoch W.J., Wilken C., Young D.A.: Sequence of apoptosis andinflammatory necrosis within the formative ovulatory site of sheepfollicles. J. Reprod. Fertil., 1999; 117: 325-329
  Google Scholar
• 49. Niquet J., Seo D.W., Wasterlain C.G.: Mitochondrial pathways ofneuronal necrosis. Biochem. Soc. Trans., 2006; 34: 1347-1351
  Google Scholar
• 50. Piotrowska A., Izykowska I., Podhorska-Okołów M. Zabel M.,Dziegiel P.: Budowa białek z rodziny NF-κB i ich rola w procesie apoptozy.Postępy Hig. Med. Dośw., 2008; 62: 64-74
  Google Scholar
• 51. Polewska J.: Autofagia – mechanizm molekularny, apoptozai nowotwory. Postępy Hig. Med. Dośw., 2012; 66: 921-936
  Google Scholar
• 52. Poon I.K., Hulett M.D., Parish C.R.: Molecular mechanisms of lateapoptotic/necrotic cell clearance. Cell Death Differ., 2010; 17: 381-397
  Google Scholar
• 53. Przybylski G, Wielikdzień J., Kopiński P.: Mechanizmy zaprogramowanejśmierci efektorowych limfocytów T. Postępy Hig. Med.Dośw., 2013; 67: 1374-1390
  Google Scholar
• 54. Rupniewska Z., Bojarska-Junak A.: Apoptoza: Przepuszczalnośćbłony mitochondrialnej i rola pełniona przez białka z rodziny Bcl-2.Postępy Hig. Med. Dośw., 2004; 58: 538-547
  Google Scholar
• 55. Saddoughi S.A., Gencer S., Peterson Y.K., Ward K.E., MukhopadhyayA., Oaks J., Bielawski J., Szulc Z.M., Thomas R.J., Selvam S.P.,Senkal C.E., Garrett-Mayer E., De Palma R.M., Fedarovich D., Liu A.i wsp.: Sphingosine analogue drug FTY720 targets I2PP2A/SET andmediates lung tumour suppression via activation of PP2A-RIPK1-dependentnecroptosis. EMBO Mol. Med., 2013; 5: 105-121
  Google Scholar
• 56. Scaffidi P., Misteli T., Bianchi M.E.: Release of chromatin proteinHMGB1 by necrotic cells triggers inflammation. Nature, 2002;418: 191-195
  Google Scholar
• 57. Siu W.P., Pun P.B., Latchoumycandane C., Boelsterli U.A.: Bax-mediatedmitochondrial outer membrane permeabilization (MOMP),distinct from the mitochondrial permeability transition, is a keymechanism in diclofenac-induced hepatocyte injury: multiple protectiveroles of cyclosporin A. Toxicol. Appl. Pharmacol., 2008; 227:451-461
  Google Scholar
• 58. Smith C.C., Davidson S.M., Lim S.Y. Simpkin J.C., Hothersall J.S.,Yellon D.M.: Necrostatin: a potentially novel cardioprotective agent?Cardiovasc. Drugs Ther., 2007; 21: 227-233
  Google Scholar
• 59. Tait S.W., Green D.R.: Caspase-independent cell death: leavingthe set without the final cut. Oncogene, 2008; 27: 6452-6461
  Google Scholar
• 60. Thorburn A.: Death receptor-induced cell killing. Cell. Signal.,2004; 16: 139-144
  Google Scholar
• 61. Trichonas G., Murakami Y., Thanos A. Morizane Y., Kayama M.,Debouck C.M., Hisatomi T., Miller J.W., Vavvas D.G.: Receptor interactingprotein kinases mediate retinal detachment-induced photoreceptornecrosis and compensate for inhibition of apoptosis. Proc.Natl. Acad. Sci. USA, 2010; 107: 21695-21700
  Google Scholar
• 62. Upton J.W., Kaiser W.J., Mocarski E.S.: Virus inhibition of RIP3–dependent necrosis. Cell Host Microbe, 2010; 7: 302-313
  Google Scholar
• 63. Vanden Berghe T., Grootjans S., Goossens V. Dondelinger Y.,Krysko D.V., Takahashi N., Vandenabeele P.: Determination of apoptoticand necrotic cell death in vitro and in vivo. Methods, 2013;61: 117-129
  Google Scholar
• 64. Vandenabeele P., Melino G.: The flick of a switch: which deathprogram to choose? Cell Death Differ., 2012; 19: 1093-1095
  Google Scholar
• 65. Vanlangenakker N., Vanden Berghe T., Vandenabeele P.: Manystimuli pull the necrotic trigger, an overview. Cell Death Differ.,2012; 19: 75-86
  Google Scholar
• 66. Willingham S.B., Allen I.C., Bergstralh D.T. Brickey W.J., HuangM.T., Taxman D.J., Duncan J.A. Ting J.P.: NLRP3 (NALP3, Cryopyrin)facilitates in vivo caspase-1 activation, necrosis, and HMGB1 releasevia inflammasome-dependent and -independent pathways. J.Immunol., 2009; 183: 2008-2015
  Google Scholar
• 67. Wu W., Liu P., Li J.: Necroptosis: an emerging form of programmedcell death. Crit. Rev. Oncol. Hematol., 2012; 82: 249-258
  Google Scholar
• 68. Yuan J., Kroemer G.: Alternative cell death mechanisms in developmentand beyond. Genes Dev., 2010; 24: 2592-2602
  Google Scholar
• 69. Zhivotovsky B., Orrenius S.: Clinical perspectives of cell death:where we are and where to go. Apoptosis, 2009; 14: 333-335
  Google Scholar
• 70. Zielinski R.R., Eigl B.J., Chi K.N.: Targeting the apoptosis pathwayin prostate cancer. Cancer J., 2013; 19: 79-89
  Google Scholar
• 71. Zong W.X., Thompson C.B.: Necrotic death as a cell fate. GenesDev., 2006; 20: 1-15
  Google Scholar

Full text